Effects of Liraglutide Combined with Insulin on Oxidative Stress and Serum MCP-1 and NF-kB Levels in Type 2 Diabetes
Open accessAbstract
OBJECTIVE: To investigate the effects of liraglutide combined with insulin on oxidative stress and expression levels of serum monocyte chemoattractant protein-1 (MCP-1) and nuclear factor-kB (NF-kB) in patients with type 2 diabetes. STUDY DESIGN: An experimental study. PLACE AND DURATION OF STUDY: Department of Endocrinology, the Second Hospital Affiliated to Lanzhou University, China, from September 2016 to January 2018. METHODOLOGY: Ninety-two patients with type 2 diabetes were selected as objects of study. They were randomly divided into observation group and control group, with 46 cases in each group. The control group was treated with insulin alone, and the observation group was treated with liraglutide in combination with insulin. The changes of levels of blood glucose, serum MDA, SOD, MCP-1 and NF-kB were compared between the two groups before and after treatment, and the blood glucose target rate after treatment was compared between the two groups. RESULTS: Before treatment, there were no significant differences in fasting blood glucose, 2h postprandial blood glucose, serum MDA, serum SOD, serum MCP-1 and serum NF-kB between the two groups (p=0.885, 0.961, 0.919, 0.990, 0.954 and 0.837, respectively). After treatment, levels of the fasting blood glucose, 2h postprandial blood glucose, serum MDA, serum MCP-1, and serum NF-kB in the observation group were lower than those in the control group (all p<0.001). The serum SOD level and blood glucose target rate were higher in the observation group than those in the control group (p<0.001 and p=0.010, respectively). CONCLUSION: Liraglutide combined with insulin therapy can effectively improve blood glucose levels in type 2 diabetic, reduce oxidative stress status, decrease the expression of serum MCP-1 and NF-kB, and inhibit the internal inflammatory response.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Evidence for oxidative stress markers like malondialdehyde is promising but varied, with some trials showing clear superiority of GLP-1 receptor agonists over insulin or metformin.
“Similarly, evidence for oxidative stress markers like MDA is promising but varied, with some trials showing clear superiority of GLP-1 RAs over insulin or metformin (9, 21, 22).”
Cited by
Sorted by citations
Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194 · see citing works
“They comprised 6749 patients (inflammation evaluated in 6560, oxidative stress in 701 patients), included a median (IQR) study population of 60 (33-122) participants, and had a median (IQR) follow-up of 6 months (84-182 days).”
BackgroundSilva, D. V. T. D., Baião, D. D. S., Ferreira, V. F., & Paschoalin, V. M. F. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1822277 · Cited by 118 · see citing works
Luna-Marco, C., Iannantuoni, F., Hermo-Argibay, A., Devos, D., Salazar, J. D., Víctor, V. M., & Rovira-Llopis, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.01.015 · Cited by 114 · see citing works
Dogan, A. D. A., Hilberg, O., Hess, S., Jensen, T. T., Bladbjerg, E.-M., & Juhl, C. B. (2022) · International Journal of COPD · doi:10.2147/copd.s350133 · Cited by 64 · see citing works
“GLP-1RAs also exhibit anti-inflammatory properties that result in reduced concentrations of interleukin-6 and monocyte chemoattractant protein-1 and, in the lungs, GLP-1 promotes vasodilation, surfactant production, and bronchodilation.(13,14) The effects of the GLP-1RAs liraglutide and exenatide have been tested in a…”
BackgroundThe Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease
Wang, W., Mei, A., Qian, H., Li, D., Xu, H., Chen, J., Yang, H., Min, X., Li, C., Li, C., et al. (2023) · International Journal of COPD · doi:10.2147/copd.s393323 · Cited by 55 · see citing works
Ullah, A., & Shen, B.-R. (2025) · European journal of medicinal chemistry · doi:10.1016/j.ejmech.2025.118065 · Cited by 38 · see citing works
Braun, M., Boström, G., Ingelsson, M., Kilander, L., Löwenmark, M., Nyholm, D., Burman, J., Niemelä, V., Freyhult, E., Kultima, K., et al. (2023) · Fluids and Barriers of the CNS · doi:10.1186/s12987-023-00472-x · Cited by 31 · see citing works
“It is associated with oxidative stress, and could therefore indirectly affect progression in several diseases such as atherosclerosis, diabetes, and AD [21–23].”
BackgroundMashayekhi, M., Beckman, J. A., Nian, H., Garner, E. M., Mayfield, D., Wright, P., Howard, S. E., Perkins, B., Olson, D., Snyder, W. E., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14903 · Cited by 43 · see citing works
“antagonism with exendin (9-39) increased fasting blood glucose but did not change”
BackgroundMethodInfluentialCheng, Y., Yang, Z.-L., Shi, J., Yang, J.-J., Zhao, J.-G., He, Y., & Qi, M.-Y. (2019) · Environmental Toxicology · doi:10.1002/tox.22864 · Cited by 27
“while testicular macrophages are the largest immune cell population in the regulatory region.(38,39) TGF-β1 is expressed by Sertoli cells and may play a role in spermatogenesis.”
BackgroundThe effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
Sivalingam, S., Larsen, E. L., van Raalte, D. V., Muskiet, M. H., Smits, M., Tonneijck, L., Joles, J., von Scholten, B. J., Zobel, E., Persson, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90191-w · Cited by 16 · see citing works
Hachuła, M., Basiak, M., Kosowski, M., & Okopień, B. (2024) · Life · doi:10.3390/life14060690 · Cited by 15 · see citing works
“Additional studies, especially randomized clinical trials with long-term observation, are needed to un-questionably assess the effect of this group of drugs on the development of atherosclerotic cardiovascular disease.”
BackgroundHuang, Z.-F., Chen, J., Wang, C., Xiao, M., Zhu, Y., Li, N., Huang, Z.-R., Liu, B., & Huang, Y. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105489 · Cited by 10
James, S., Christoffersen, A. D., David, J., Hacker, M., Jensen, M. D. R. J., Mellbin, L., Pieber, T., Ripa, R. S., Rossing, P., Svehlikova, E., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.05.001 · Cited by 9 · see citing works
Bajic, Z., Sobot, T., Šmitran, A., Uletilović, S., Mandić-Kovačević, N., Cvjetković, T., Maličević, U., Stanetić, B., Đukanović, Đ., Matičić, M., et al. (2025) · Life · doi:10.3390/life15030443 · Cited by 8 · see citing works
“Recent studies have revealed that liraglutide exhibits beneficial effects, including its role in reducing inflammation [16] and oxidative stress [17].”
Kher, M., Beri, S., Rehan, H., Prakash, A., & Gupta, L. (2020) · Diabetes & metabolic syndrome · doi:10.1016/j.dsx.2020.08.016 · Cited by 8 · see citing works
Li, M., Xu, S., Cai, H., Xiao, J., & Qin, Y. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156547 · Cited by 8 · see citing works
Bai, J., Zhang, L., He, L., & Zhou, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1613640 · Cited by 6 · see citing works
Wang, L., Liu, X.-Y., Yang, W., Lai, J.-B., Yu, X., Liu, J.-R., Gao, X., Jie, M., Ma, K.-Y., Xu, J., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00904-z · Cited by 6 · see citing works
Self-citationGLP-1RAs: antidiabetic drug crossover—new hope for chronic inflammatory airway diseases
Chen, Y., Shen, Y., Shen, H., & Liu, Z. (2026) · Respiratory Research · doi:10.1186/s12931-026-03569-7 · Cited by 5 · see citing works
“More specifically, this synergistic effect was demonstrated by the ability to reduce serum MDA, MCP-1, and NF-κB expression and elevate serum superoxide dismutase expression levels [29].”
Jiménez-López, R., Martín-Chaves, L., Gutiérrez-García, Á. M., Carmona-Segovia, A. D. M., Mora-Ordóñez, B., García, A. M. S., Fernández-Romero, L., Murri, M., Sanchez‐Quintero, M. J., García, G. B., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1631334 · Cited by 7 · see citing works
Alrasheed, T., Mostafa, M. E. A., Madkhali, M. A., & Khairy, H. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1734549 · Cited by 4 · see citing works
Kanbay, M., Shah, E., AlShiab, R., Ozbek, L., Ay, S., Rustamov, A., Covic, A., Mallamaci, F., & Zoccali, C. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.71106 · Cited by 4 · see citing works
State of the Art Review: Glucagon-Like Peptide-1 in Obesity-Related Asthma
Gomez, D. R., Swartzman, I., Linderholm, A., Cummings, B. P., Zeki, A. A., Sundar, K. M., & Kenyon, N. J. (2025) · Lung · doi:10.1007/s00408-025-00861-z · Cited by 3 · see citing works
“…models as well, where GLP-1 receptor activation reduces levels of IL-6, TNF-α, reduced oxidative stress markers, increased antioxidant levels, and lowered pro-inflammatory markers, MCP-1 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), as compared to insulin alone [98].”
Fanizza, J., Moghaddam, A., & Atrash, A. (2026) · Journal of clinical anesthesia · doi:10.1016/j.jclinane.2026.112192 · Cited by 2 · see citing works
Weber, P., Meluzínová, H., & Weberová, D. (2022) · Klinická farmakologie a farmacie · doi:10.36290/far.2021.027
Effect of oral antihyperglycemic drugs on purine metabolism
Panevin, T. (2021) · Diabetes mellitus · doi:10.14341/dm12756
- Authors
- Liu, X., Huang, J., Li, J., Mao, Q., & He, J.
- Affiliations
- Lanzhou University Second Hospital (CN)
- Gansu University of Traditional Chinese Medicine (CN)
- Jining First People's Hospital (CN)
- Venue
- Journal of the College of Physicians and Surgeons Pakistan
- Published
- 2019-03-01
- Volume
- 29
- Issue
- 3
- Pages
- 218-221
- ISSN
- 1022-386X (ISSN-L)
- 1681-7168
- OpenAlex
- W2918520030
- Cited by
- 28
- References
- 0
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 1 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 3 · 2019: 1
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Journal of College of Physicians And Surgeons Pakistan (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- liraglutide, insulin, type 2 diabetes, oxidative stress, MCP-1, malondialdehyde, superoxide dismutase, glycemic control, inflammation
- MeSH terms
- Liraglutide, Adult, Aged, Blood Glucose, China, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Enzyme-Linked Immunosorbent Assay, Female, Hospitals, University, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Prognosis, Reference Values, Severity of Illness Index, NF-kappa B, Treatment Outcome, Oxidative Stress, Chemokine CCL2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
